451 related articles for article (PubMed ID: 33562668)
41.
Boyle EM; Ashby C; Tytarenko RG; Deshpande S; Wang H; Wang Y; Rosenthal A; Sawyer J; Tian E; Flynt E; Hoering A; Johnson SK; Rutherford MW; Wardell CP; Bauer MA; Dumontet C; Facon T; Thanendrarajan S; Schinke CD; Zangari M; van Rhee F; Barlogie B; Cairns D; Jackson G; Thakurta A; Davies FE; Morgan GJ; Walker BA
Clin Cancer Res; 2020 May; 26(10):2422-2432. PubMed ID: 31988198
[TBL] [Abstract][Full Text] [Related]
42. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
Oben B; Froyen G; Maclachlan KH; Leongamornlert D; Abascal F; Zheng-Lin B; Yellapantula V; Derkach A; Geerdens E; Diamond BT; Arijs I; Maes B; Vanhees K; Hultcrantz M; Manasanch EE; Kazandjian D; Lesokhin A; Dogan A; Zhang Y; Mikulasova A; Walker B; Morgan G; Campbell PJ; Landgren O; Rummens JL; Bolli N; Maura F
Nat Commun; 2021 Mar; 12(1):1861. PubMed ID: 33767199
[TBL] [Abstract][Full Text] [Related]
43. Low-depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution.
Elnenaei MO; Knopf P; Cutler SD; Sinclair K; Abou El Hassan M; Greer W; Goudie M; Wagner J; White D; Couban S; Forward N; Gaston D; Campbell CJV
Clin Genet; 2019 Aug; 96(2):163-168. PubMed ID: 31066036
[TBL] [Abstract][Full Text] [Related]
44. [Cytogenetic and molecular basis of multiple myeloma].
Taniwaki M; Matsumoto Y
Nihon Rinsho; 2007 Dec; 65(12):2179-86. PubMed ID: 18069258
[TBL] [Abstract][Full Text] [Related]
45. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
46. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.
Garcés JJ; Bretones G; Burgos L; Valdes-Mas R; Puig N; Cedena MT; Alignani D; Rodriguez I; Puente DÁ; Álvarez MG; Goicoechea I; Rodriguez S; Calasanz MJ; Agirre X; Flores-Montero J; Sanoja-Flores L; Rodriguez-Otero P; Rios R; Martinez-Lopez J; Millacoy P; Palomera L; Del Orbe R; Pérez-Montaña A; El Omri H; Prosper F; Mateos MV; Rosiñol L; Blade J; Lahuerta JJ; Orfao A; Lopez-Otin C; San Miguel JF; Paiva B;
Leukemia; 2020 Nov; 34(11):3007-3018. PubMed ID: 32475991
[TBL] [Abstract][Full Text] [Related]
47. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
[TBL] [Abstract][Full Text] [Related]
48. Genome instability in multiple myeloma.
Neuse CJ; Lomas OC; Schliemann C; Shen YJ; Manier S; Bustoros M; Ghobrial IM
Leukemia; 2020 Nov; 34(11):2887-2897. PubMed ID: 32651540
[TBL] [Abstract][Full Text] [Related]
49. Integration of Genomics Into Treatment: Are We There Yet?
Morgan GJ; Jones JR
Am Soc Clin Oncol Educ Book; 2017; 37():569-574. PubMed ID: 28561666
[TBL] [Abstract][Full Text] [Related]
50. Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity.
Sticca T; Caberg JH; Wenric S; Poulet C; Herens C; Jamar M; Josse C; El Guendi S; Max S; Beguin Y; Gothot A; Caers J; Bours V
Genes Chromosomes Cancer; 2017 Jan; 56(1):18-27. PubMed ID: 27454822
[TBL] [Abstract][Full Text] [Related]
51. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.
Pickering CR; Zhang J; Yoo SY; Bengtsson L; Moorthy S; Neskey DM; Zhao M; Ortega Alves MV; Chang K; Drummond J; Cortez E; Xie TX; Zhang D; Chung W; Issa JP; Zweidler-McKay PA; Wu X; El-Naggar AK; Weinstein JN; Wang J; Muzny DM; Gibbs RA; Wheeler DA; Myers JN; Frederick MJ
Cancer Discov; 2013 Jul; 3(7):770-81. PubMed ID: 23619168
[TBL] [Abstract][Full Text] [Related]
52. Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.
Kjeldsen E
Cancer Genomics Proteomics; 2016; 13(2):91-127. PubMed ID: 26912802
[TBL] [Abstract][Full Text] [Related]
53. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.
Moreau P; Facon T; Leleu X; Morineau N; Huyghe P; Harousseau JL; Bataille R; Avet-Loiseau H;
Blood; 2002 Sep; 100(5):1579-83. PubMed ID: 12176874
[TBL] [Abstract][Full Text] [Related]
54. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.
Gutiérrez NC; García JL; Hernández JM; Lumbreras E; Castellanos M; Rasillo A; Mateo G; Hernández JM; Pérez S; Orfao A; San Miguel JF
Blood; 2004 Nov; 104(9):2661-6. PubMed ID: 15238415
[TBL] [Abstract][Full Text] [Related]
55. Prognosis, Biology, and Targeting of
Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
[TBL] [Abstract][Full Text] [Related]
56. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Carrasco DR; Tonon G; Huang Y; Zhang Y; Sinha R; Feng B; Stewart JP; Zhan F; Khatry D; Protopopova M; Protopopov A; Sukhdeo K; Hanamura I; Stephens O; Barlogie B; Anderson KC; Chin L; Shaughnessy JD; Brennan C; Depinho RA
Cancer Cell; 2006 Apr; 9(4):313-25. PubMed ID: 16616336
[TBL] [Abstract][Full Text] [Related]
57. [Advances in multiple myeloma molecular biology research].
Hanamura I
Rinsho Ketsueki; 2019; 60(9):1236-1242. PubMed ID: 31597849
[TBL] [Abstract][Full Text] [Related]
58. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.
Manier S; Park J; Capelletti M; Bustoros M; Freeman SS; Ha G; Rhoades J; Liu CJ; Huynh D; Reed SC; Gydush G; Salem KZ; Rotem D; Freymond C; Yosef A; Perilla-Glen A; Garderet L; Van Allen EM; Kumar S; Love JC; Getz G; Adalsteinsson VA; Ghobrial IM
Nat Commun; 2018 Apr; 9(1):1691. PubMed ID: 29703982
[TBL] [Abstract][Full Text] [Related]
59. From Bench to Bedside: The Evolution of Genomics and Its Implications for the Current and Future Management of Multiple Myeloma.
Morgan GJ; Boyle EM; Davies FE
Cancer J; 2021 May-Jun 01; 27(3):213-221. PubMed ID: 34549910
[TBL] [Abstract][Full Text] [Related]
60. Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.
Perrot A; Corre J; Avet-Loiseau H
Am Soc Clin Oncol Educ Book; 2018 May; 38():675-680. PubMed ID: 30231368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
